壳聚糖球形多孔微载体支持下人肝细胞L-02的高浓度细胞培养

背景：微载体培养技术作为一项体外高浓度细胞培养技术,近年来已在肝细胞的体外培养中得到应用。 目的：对壳聚糖球形多孔微载体培养的人肝细胞L-02进行定时的形态学观察。 方法：以自制的壳聚糖球形多孔微载体样本为支架来培养人肝细胞L-02设为实验组;无壳聚糖球形多孔微载体支持下人肝细胞的培养设为对照组。对两组细胞进行定时的细胞计数,并对实验组进行形态学观察,包括倒置相差生物显微镜观察和扫描电子显微镜观察。 结果：两组培养的细胞数量均呈现前3 d增长,在第3天细胞数量达到最高值;而且实验组3个样本培养的细胞数明显高于对照组无微载体培养的细胞数量(P < 0.05),实验组各样本之间差异无显著性意义(P > 0.05);倒置相差生物显微镜下动态观察,可见前3 d微载体表面黏附生长的肝细胞则逐渐增多,第3天可见大部分微载体表面有许多肝细胞黏附成团,总的存活率均在90%以上,且肝细胞保持着良好的形态学结构;扫描电子显微镜观察,微载体表面、切面和内部均可看到有许多球状肝细胞紧密黏附。提示,以自制的壳聚糖球形多孔微载体作为一种支架,在体外三维环境下可以进行高浓度细胞培养。     

球形多孔微载体支持下高密度培养人肝细胞L-02的定时形态变化

背景：微载体培养技术作为一项体外高浓度细胞培养技术,近年来已在肝细胞的体外培养中得到应用。 目的：对壳聚糖球形多孔微载体培养的人肝细胞L-02进行定时的形态学观察。 方法：以自制的壳聚糖球形多孔微载体样本为支架来培养人肝细胞L-02设为实验组;无壳聚糖球形多孔微载体支持下人肝细胞的培养设为对照组。对两组细胞进行定时的细胞计数,对实验组进行形态学观察,包括倒置相差生物显微镜观察和扫描电子显微镜观察。 结果与结论：两组培养的细胞数量均呈现前3 d增长,在培养第3天细胞数量达到最高值;实验组3个样本培养的细胞数明显高于对照组无微载体培养的细胞数量(P < 0.05),实验组各样本之间细胞数差异无显著性意义(P > 0.05)。倒置相差生物显微镜下动态观察,可见前3 d微载体表面黏附生长的肝细胞则逐渐增多,培养第3天可见大部分微载体表面有许多肝细胞黏附成团,总的存活率均在90%以上,且肝细胞保持着良好的形态学结构;扫描电子显微镜观察,微载体表面、切面和内部均可看到有许多球状肝细胞紧密黏附。结果说明,以自制的壳聚糖球形多孔微载体作为一种支架,在体外三维环境下可以进行高浓度细胞培养。中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程全文链接：     

抗凝血纳米壳聚糖微球的合成、表征及生物安全性评价

 背景：有研究显示,壳聚糖等天然多糖经磺化改性后具有类似肝素的抗凝功能,因磺酸化后的壳聚糖其形成的磺酸根基团与肝素的活性基团相似,具有良好的抗凝血性。 目的：制备具有抗凝血功能的纳米壳聚糖微球,检测其形态结构、理化性能及生物安全性。 方法：利用乳相法合成纳米壳聚糖微球,通过磺化反应合成磺酸化壳聚糖微球,通过透射电镜描述其形态特征,红外光谱观察其特异基团峰值变化。①凝血实验：分别将肝素、纳米壳聚糖微球及10,30,50 mg磺酸化壳聚糖微球加入SD大鼠血中,检测凝血指标。②溶血实验：分别将去离子水、生理盐水及10,30,50 g/L磺酸化壳聚糖微球浸提液加入兔2%红细胞悬液中,检测溶血率。③细胞毒性实验：分别采用含体积分数10%胎牛血清的DMEM培养基及10,30,50 g/L磺酸化壳聚糖微球的浸提液培养人脐静脉血管内皮细胞,72 h后检测细胞相对增殖率及毒性分级。 结果与结论：扫描电镜显示磺酸化壳聚糖微球具有良好的形态结构,粒径大小50 nm,红外图谱提示存在磺化取代。体外凝血实验表明磺酸化壳聚糖微球具有显著抗凝血作用,抗凝血效果呈剂量效应关系。磺酸化壳聚糖微球符合国标关于溶血率小于5%的安全标准,无致溶血性。细胞毒性实验表明磺酸化壳聚糖微球浸提液无明显细胞毒性,其生物安全性符合国家标准。 中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程     

去白细胞采输血器的血液相容性体外评价

去白细胞采输血器是用于过滤全血或红细胞悬液中白细胞的医疗器械类产品,为保证其临床应用的安全性,本文对去白细胞采输血器（型号：NGL/RF-XZ-200）进行血液相容性体外评价.选择去白细胞采输血器的3个主要部件：软管、塑料血袋和去白细胞滤器滤膜为试验样品,以进口同类产品作为参照,按照GB/T 16886.4-2003和GB/T 14233.2-2005标准的要求和方法,进行溶血、PTT以及体外自发性血小板聚集3个体外血液相容性指标测试.结果 显示试验样品溶血率小于5%,样品凝血时间和血小板最大聚集率与参照样品无显著性差异（P〉0.05）.该结果表明去白细胞采输血器对血液成分和功能无明显不良影响,具有良好的血液相容性.     

球形多孔微载体支持下高密度培养人肝细胞L-02的定时形态变化（英文）

背景:微载体培养技术作为一项体外高浓度细胞培养技术,近年来已在肝细胞的体外培养中得到应用。目的:对壳聚糖球形多孔微载体培养的人肝细胞L-02进行定时的形态学观察。方法:以自制的壳聚糖球形多孔微载体样本为支架来培养人肝细胞L-02设为实验组;无壳聚糖球形多孔微载体支持下人肝细胞的培养设为对照组。对两组细胞进行定时的细胞计数,对实验组进行形态学观察,包括倒置相差生物显微镜观察和扫描电子显微镜观察。结果与结论:两组培养的细胞数量均呈现前3 d增长,在培养第3天细胞数量达到最高值;实验组3个样本培养的细胞数明显高于对照组无微载体培养的细胞数量(P0.05),实验组各样本之间细胞数差异无显著性意义(P0.05)。倒置相差生物显微镜下动态观察,可见前3 d微载体表面黏附生长的肝细胞则逐渐增多,培养第3天可见大部分微载体表面有许多肝细胞黏附成团,总的存活率均在90%以上,且肝细胞保持着良好的形态学结构;扫描电子显微镜观察,微载体表面、切面和内部均可看到有许多球状肝细胞紧密黏附。结果说明,以自制的壳聚糖球形多孔微载体作为一种支架,在体外三维环境下可以进行高浓度细胞培养。     

磁性壳聚糖微球的生物相容性

背景：采用壳聚糖对磁性氧化铁纳米颗粒表面进行改性,一方面可改善磁性纳米氧化铁颗粒的团聚性,增加其稳定性,另一方面将来可用于肿瘤热疗及基因治疗。 目的：制备将来可用于肿瘤热疗及基因治疗的磁性壳聚糖微球,评价其生物相容性。 方法：采用改良的化学沉淀法制备磁性氧化铁纳米颗粒。采用超声乳化法将壳聚糖加入到磁性氧化铁纳米颗粒中制备磁性壳聚糖微球,进行以下实验：①MTT实验检测磁性壳聚糖微球浸提液的细胞毒性：分别以1640培养液、聚丙烯酰胺单体溶液、100%,75%,50%,25%的磁性壳聚糖微球浸提液培养L-929细胞。②溶血实验：在兔抗凝血中分别加入磁性壳聚糖微球浸提液、生理盐水及蒸馏水。③微核实验：在昆明小鼠腹腔分别注射含氧化铁磁流体5,3.75,2.5,1.25 g/kg的磁性壳聚糖微球混悬液、环磷酰胺及生理盐水。 结果与结论：磁性壳聚糖微球粒径200-300 nm,分散效果有所提高。不同浓度的磁性壳聚糖微球浸提液对L-929 细胞毒性为1级,属对细胞无毒性范畴。磁性壳聚糖微球浸提液的溶血率为0.69%,小于5%,符合医用材料的溶血实验要求。磁性壳聚糖微球混悬液未导致细胞DNA断裂和非整倍体化,未导致微核产生的遗传毒理作用,材料无致畸或致突变作用,因此磁性壳聚糖微球具有良好的生物相容性。     

壳聚糖醋酸溶液对凝血作用的研究

研究了不同脱乙酰度和不同分子量壳聚糖醋酸溶液的凝血作用。发现壳聚糖醋酸溶液使抗凝血液中红细胞发生了明显的聚集和变形。通过不同分子量和脱乙酰度壳聚糖的促红细胞聚集实验,证明了低脱乙酰度壳聚糖(60%~70%)使红细胞聚集效果更好,分子量在105~106范围内作用不十分明显。对血液的凝血酶时间(TT)、凝血酶原时间(PT)、活化部分促凝血酶原激酶时间(APTT)和纤维蛋白原浓度(FIB)的测定结果验证了壳聚糖醋酸溶液凝血机理不依赖于血小板和常规“瀑布”凝血机制。     

碳纳米管/聚氨酯复合材料的制备及生物相容性评价

目的 制备和评价碳纳米管/聚氨酯复合材料的生物相容性。方法 通过溶胶-凝胶方法制备碳纳米管/聚氨酯复合材料,对其力学性能进行测试;根据ISO10993指南,选取溶血实验、动态凝血实验、血小板黏附实验、血小板活化实验、细胞毒性实验和材料局部植入方法对复合材料的生物相容性进行评价。结果 复合材料无明显细胞毒性,并表现出比聚氨酯材料更好的抗溶血性能、动态凝血性能、抑制血小板黏附性能以及组织相容性。结论 碳纳米管－聚氨酯复合材料具有优良的生物相容性,可以作为制备组织工程细胞生长支架、人工血管、药物载体的基础材料。     

壳聚糖球形多孔微载体支持下培养的肝细胞功能及其代谢活性检测

背景：在肝细胞移植及生物型人工肝研究中,肝细胞培养仍然是其关键,如何方便地获取足够数量、活性较好、功能良好的肝细胞已经成为其首要问题。微载体培养技术作为一项体外高密度细胞培养技术,近年来已在肝细胞的体外培养中得到应用。 目的：对壳聚糖球形多孔微载体培养的人肝细胞L-02进行定时的细胞功能和代谢活性检测。 方法：对以自制的壳聚糖球形多孔微载体样本为支架培养的人肝细胞L-02进行定时的细胞功能检测(包括测定谷草转氨酶,谷丙转氨酶和乳酸脱氢酶质量浓度)和代谢活性检测(包括检测培养基中白蛋白、尿素、葡萄糖含量),其中实验组为壳聚糖球形多孔微载体支持下培养人肝细胞L-02,对照组为无壳聚糖球形多孔微载体支持下培养人肝细胞L-02,检测时间点为人肝细胞L-02培养的第1,2,3,4,5天。 结果与结论：实验组和对照组测定的谷草转氨酶、谷丙转氨酶和乳酸脱氢酶活性在前3 d持续下降,第3天降到最低,而从第4天开始重新反弹上升;但白蛋白、尿素和葡萄糖水平在前3 d持续上升,第3天升到最高值,而从第4天开始逐渐下降,实验组每天测定上述各项水平始终明显高于对照组(P < 0.05),提示实验组中的人肝细胞L-02代谢活性较对照组增强。     

煅烧骨的安全性

背景：经高温处理的煅烧骨具有类似自然骨的连续微孔结构,良好的生物相容性和降解性。 目的：观察牛煅烧骨的生物相容性、细胞相容性及毒性。 方法：①细胞相容性实验：将牛煅烧骨与第3 代已诱导的Wistar大鼠骨髓间充质干细胞复合培养。②溶血实验：将煅烧骨浸提液、生理盐水与双蒸水加入兔血中。③凝血实验：将煅烧骨加入兔血浆中。④急性毒性实验：在昆明种小鼠尾静脉分别注射煅烧骨浸提液、生理盐水。⑤微核实验：在小鼠腹腔分别注射煅烧骨浸提液、生理盐水与环磷酰胺。⑥局部刺激性实验：将煅烧骨浸提液、生理盐水分别注射于兔两侧脊柱皮下。⑦热源检测实验：在兔耳静脉注射煅烧骨浸提液。⑧皮下植入实验：将煅烧骨材料植入Wistar大鼠背部皮下。 结果与结论：煅烧骨材料无细胞毒性,具有良好的细胞及血液相容性;对皮肤、肌肉无刺激作用;对心、肝、肾重要器官无毒性作用;皮下植入后对周围组织无刺激作用,能够部分降解吸收并被机体组织替代;无致热作用,对凝血功能无影响,对小鼠骨髓细胞无抑制及毒性作用。     

聚四氟乙烯人工血管对血小板聚集的影响及细胞相容性

BACKGROUND: Polytetrafluoroethylene artificial blood vessels have been extensively used in clinic. However, there is still a lack of basic study on it. OBJECTIVE: To observe the effect of polytetrafluoroethylene artificial blood vessels on platelet aggregation and its cytocompatibility. METHODS: Effect on platelet aggregation: Dynamic platelet clotting time and plasma recalcification time were detected. Normal saline, distilled water and polytetrafluoroethylene artificial blood vessels were added into the rabbit red cell suspensions, respectively, to count the hemolysis ratio. Cytocompatibility: Primary myocardial cells from Sprague-Dawley rats were respectively seeded onto the common round coverslip and polytetrafluoroethylene artificial blood vessels, and the lactate deshydrogenase release and cell proliferation were detected at 3 and 5 days, respectively. RESULTS AND CONCLUSION: Polytetrafluoroethylene artificial blood vessels made no effects on the platelet clotting time and plasma recalcification time and 2.3% hemolysis ratio was observed. Compared with the common round coverslip, the myocardial cell proliferation and lactate deshydrogenase release showed no significant changes on the polytetrafluoroethylene artificial blood vessels. These results suggest that the polytetrafluoroethylene artificial blood vessel makes no effect on platelet aggregation and holds good hemocompatibility and cytocompatibility.     

Extensive coagulation monitoring in patients after implantation of the MicroMed Debakey continuous flow axial pump

Ventricular assist device (VAD) implantation is associated with impaired primary hemostasis and thromboembolic complications. Recently, a new generation of implantable continuous flow axial pumps was introduced into clinical application. To study the potential thrombogenic properties of this type of pump, we applied extensive platelet monitoring was applied. In our institution, 13 patients received the MicroMed DeBakey VAD as a bridge to transplantation. Routine coagulation tests (platelet count, activated partial thromboplastin time, prothrombin time, antithrombin III activity) and platelet function tests (whole blood aggregometry, thrombelastography, flow cytometry) were performed. No clinically relevant thromboembolic events were detected. No correlation was found between global function tests, platelet aggregation, and thrombelastography. No correlation was detected between platelet activation and hemolysis parameters. Platelet aggregation and coagulation index were significantly suppressed early after operation. A subsequent phase of hyper-aggregability, starting around day 6, suggested the initiation of antiaggregation therapy. Platelet activation markers were upregulated in the postoperative period but were returned to preoperative levels after initiation of aspirin. In contrast to routine coagulation monitoring, platelet function tests reflect in detail the coagulation status of blood pump recipients and the efficiency of antiaggregation therapy. Aspirin and dipyridamole therapy in addition to oral anticoagulation using phenprocoumon may contribute to platelet function and clot mechanics restoration and is, therefore, recommended for patients after VAD implantation.     

Effect of intravenous prostaglandin E2 on platelet function, coagulation, and fibrinolysis

Prostaglandin E(2) (PGE(2)) was infused intravenously to eight women for the termination of pregnancy and tests of platelet function: coagulation and fibrinolysis were studied before and during the infusion.Platelet adhesiveness, as measured by a cellophane membrane test-cell system, was significantly diminished by PGE(2), a change which was not noted by the glass-bead column technique. The administration of PGE(2) caused more rapid platelet disaggregation following ADP-induced aggregation but had no effect on the platelet count, collagen-induced aggregation, or platelet factor 3 activity. An increase in plasma antithrombin concentration and euglobulin lysis activity was also noted.These results support the concept that prostaglandin E(2) might have a role in the prevention of thrombosis.     

应用Triton-x100加丹参酚酸B制备脱细胞血管支架及其血液相容性研究

应用传统的Triton-x100法与应用Triton-x100和丹参酚酸B法制备脱细胞血管支架,比较这两种支架的理化性质及其血液相容性,展望应用丹参酚酸B后处理脱细胞血管支架在临床上治疗心脑血管疾病方面的应用前景,以及在组织工程血管材料方面的开发空间。选择SD大鼠16只,雄性,鼠龄7周,体质量250 g左右。解剖大鼠,取腹主动脉;随机分为2组,每组8个。用Triton-x100法(Tx组)、Triton-x100加入丹参酚酸B法(Tx-sal 组),加工制成两种脱细胞血管支架。观察脱细胞血管支架的宏观形貌;亲水性实验测定亲水性;体外溶血实验计算体外溶血率;复钙化凝血时间实验测定复钙化凝血时间;血小板黏附实验测定动态凝血时间,以及体外血小板的黏附;补体激活实验测定补体激活程度情况;比较两组脱细胞血管支架的血液相容性。Tx组接触角为76.36°±4.65°,Tx-sal组接触角为71.26°±3.55°,Tx组接触角度数略高于Tx-sal 组,差异无显著统计学意义。Tx-sal 组溶血率为1.5%,Tx组溶血率为2.1%。Tx组复钙化凝血时间为(212±11.32)s,Tx-sal 组复钙化凝血时间为(231±13.53)s,Tx组与Tx-sal 组的复钙化凝血时间差异有显著统计学意义。Tx-sal组相比Tx组延缓了凝血时间,抗凝血性更加优良。Tx-sal 组黏附的血小板数目低于Tx组的相应数目。Tx-sal 组补体激活水平低。与传统的Triton-x100法制备的脱细胞血管支架相比,加入丹参酚酸B后处理的脱细胞血管支架具有更加优良的血液相容性,更适合作为组织工程材料应用于心脑血管疾病的治疗,在临床医学上的应用前景更加广阔。     

Effect of albumin coating on the in vitro blood compatibility of Dacron arterial prostheses

A recirculating in vitro perfusion system was used to assess the effect of albumin precoating on the thrombogenicity of Dacron vascular grafts. A complete analysis of platelet activation was carried out, involving platelet count, release, adhesion and aggregation. Fibrin formation was assessed by measuring fibrinogen levels and fibrinopeptide A production; leucocyte interaction was analysed by measuring total leucocyte count as well as an analysis of cell adhesion to the surface by scanning electron microscopy. The platelet count decreased progressively with perfusion time for Dacron until by 30 min, it had declined to 69% +/- 2% of baseline. The platelet count did not, however, change significantly from baseline when albumin-coated Dacron was tested. Release of platelet factor 4 and beta-thromboglobulin at 180 min for Dacron was 37.8 +/- 29.8 times and 66.9 +/- 18.2 times baseline, respectively, while albumin coating caused significantly less (P less than 0.03) platelet release. Albumin coating diminished coagulation activation and fibrinopeptide A formation. The total leucocyte concentration decreased significantly for Dacron by 180 min, while that for albumin-coated Dacron did not change significantly from baseline levels. Albumin coating produced a film-like covering over the Dacron. For Dacron, there were numerous leucocytes and platelets adherent to the surface, whilst cellular deposition was minimal upon the albumin-coated surface. Thus, albumin coating improved the short-term blood compatibility of Dacron by all of the methods employed in this study.     

壳聚糖与海藻酸钙双相陶瓷骨支架的机械性能及细胞相容性

BACKGROUND: Hydroxyapatite/β-tricalcium phosphate biphasic ceramic bone has good cell compatibility, but its mechanical properties are poor. OBJECTIVE: To construct chitosan/ or calcium alginate/biphasic ceramic bone scaffolds and to detect their mechanical properties and cytocompatibility. METHODS: Different concentrations of chitosan (2%, 4%, 7%, 10%) or calcium alginate (3%, 4%, 5%, 7%) were mixed with biphasic ceramic bone to prepare chitosan/biphasic ceramic bone scaffold and calcium alginate/biphasic ceramic bone scaffold. Their morphology and structure, coagulation time, anti-dissolution properties, shear force, compressive strength and cell compatibility were detected. RESULTS AND CONCLUSION: (1) Coagulation time: with the concentration increase, the initial and final setting time of these two kinds of composite scaffolds were prolonged to some extent. (2) Scanning electron microscopy: these two kinds of composite scaffolds showed porous microstructures with different pore sizes. (3) Anti-dissolution properties: the calcium alginate/biphasic ceramic bone scaffold (3%, 4%, 5%, 7%) and chitosan/biphasic ceramic bone scaffold (7%, 10%) had good anti-dissolution properties in the liquid. (4) Mechanical strength: with the concentration increase, the shear force and compressive strength of the calcium alginate/biphasic ceramic bone scaffold were reduced. (5) Cell compatibility: the cytotoxicity of chitosan/ or calcium alginate/biphasic ceramic bone scaffolds was graded as 0-1 or 2-3, respectively. These results show that the chitosan/biphasic ceramic bone scaffold has better mechanical properties and cell compatibility than the calcium alginate/biphasic ceramic bone scaffold.      

Coagulation and complement activation

The purpose of this investigation was to assess the effect of heparin coating of a new stent construction (Stent Graft, Jomed Implantate GmbH, Germany) on platelet and coagulation activity. METHODS: Stent grafts with an ePTFE membrane interfoliated between two stents were deployed in tubings to form Chandler loops. Fresh human blood with a low concentration of heparin was rotated for 1 h, then collected and used for measurements of platelet number, thrombin-antithrombin complex (TAT), CD11b, C3a and C5b-9. There were five study groups: Group 1, conventional unmodified stents (n = 8); Group 2, untreated stent grafts (n = 8); Group 3, heparin-coated stents and untreated membrane (n = 7); Group 4, heparin-coated stents and membrane (n = 8); Group 5, heparin-coated PVC tubings with no stents (n = 8). RESULTS: There was a significant drop in platelet count, increase in TAT-values and CD11b expression in Groups 1-3 but not in Group 4 compared to Group 5. Examination by scanning electron microscopy revealed extensive activation on non-modified stents but almost no deposition of thrombotic material on heparin-modified stent grafts. CONCLUSIONS: With unmodified stents and membrane there were signs of significant activation of platelets and coagulation. In contrast, the heparin-coated stent graft induced much less alterations, indicating improved blood compatibility.     

Chronic intermittent asphyxia increases platelet reactivity in rats

Sleep-disordered breathing is associated with chronic intermittent asphyxia and with a variety of cardiovascular abnormalities. Cardiovascular morbidity and mortality are linked to altered platelet function, and platelet function is affected in sleep-disordered breathing. As there is evidence that chronic continuous hypoxia may alter platelet number and function, the aim of the present study was to test the hypothesis that chronic intermittent asphyxia affects platelet count, activation and aggregation. Rats were treated with a hypercapnic hypoxic gas mixture (minimum of 6-8% O2, maximum of 10-14% CO2) for 15 s, twice per minute for 8 h per day for 3 weeks. Blood was analysed for platelet count, platelet activation (CD62p expression using flow cytometry), response to low dose ADP, haematocrit, red cell count and haemoglobin concentration. A platelet function analyser measured the closure time of an aperture, dependent on platelet aggregation. Compared to controls (n = 16), chronic intermittent asphyxia (n = 13) reduced body weight and increased right ventricular weight but had no significant effect on platelet count (control, 880.4 +/- 20.1; treated: 914.1 +/- 35.2 x 10(3) microl(-1); mean +/- S.E.M.), on the reduction in platelet count in response to ADP (control, reduced to 206.7 +/- 49.0; treated, reduced to 193.8 +/- 35.9 x 10(3) microl(-1)), or on the percentage of platelets positive for CD62p (control, 5.2 +/- 0.7; treated, 6.0 +/- 0.8%). Chronic intermittent asphyxia significantly (P = 0.037) reduced the closure time (control, 90.9 +/- 7.7; treated, 77.7 +/- 3.8 s), indicating greater adhesion and aggregation. There was no significant difference in haematocrit, red cell count and haemoglobin concentration. In conclusion, chronic intermittent asphyxia has no effect on platelet count but does increase platelet aggegation in rats. These data support the idea that chronic intermittent asphyxia alters platelet function in sleep-disordered breathing.